Characterization of a topologically aberrant plasmid population from pilot-scale production of clinical-grade DNA

Debra Weigl1, Mike J Molloy, Tim M Clayton

  • 1BioPharmaceutical Product Development-US, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA.

Journal of Biotechnology
|September 10, 2005
PubMed

Related Concept Videos